Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 57.32M |
---|---|---|---|---|---|
Net income 2024 * | -47M | Net income 2025 * | -73M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.05
x | P/E ratio 2025 * |
-2.07
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.45% |
Latest transcript on Novus Therapeutics, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 51 | 20-04-30 | |
Paul Little
DFI | Director of Finance/CFO | 60 | 21-03-14 |
Steven N. Perrin
PSD | President | 59 | 20-09-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Keith Katkin
CHM | Chairman | 52 | 17-04-30 |
Walter C. Ogier
BRD | Director/Board Member | 67 | 20-09-13 |
John S. McBride
BRD | Director/Board Member | 72 | 17-04-30 |
1st Jan change | Capi. | |
---|---|---|
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |